Degl'Innocenti et al., 2005 - Google Patents
Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunizationDegl'Innocenti et al., 2005
View PDF- Document ID
- 12111871398781271690
- Author
- Degl'Innocenti E
- Grioni M
- Boni A
- Camporeale A
- Bertilaccio M
- Freschi M
- Monno A
- Arcelloni C
- Greenberg N
- Bellone M
- Publication year
- Publication venue
- European journal of immunology
External Links
Snippet
In the tumor‐prone transgenic adenocarcinoma mouse prostate (TRAMP) mouse model we followed the fate of the immune response against the SV40 large T antigen (Tag) selectively expressed in the prostate epithelium during the endogenous transformation from normal …
- 210000004027 cells 0 title abstract description 74
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Degl'Innocenti et al. | Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization | |
| Kerdidani et al. | Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts | |
| Smith et al. | Pancreatic gene expression in rare cells of thymic medulla: evidence for functional contribution to T cell tolerance. | |
| Kushwah et al. | Uptake of apoptotic DC converts immature DC into tolerogenic DC that induce differentiation of Foxp3+ Treg | |
| Martin‐Orozco et al. | Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells | |
| Harimoto et al. | Inactivation of tumor‐specific CD8+ CTLs by tumor‐infiltrating tolerogenic dendritic cells | |
| Yoshikawa et al. | HLA‐A2‐restricted glypican‐3 peptide‐specific CTL clones induced by peptide vaccine show high avidity and antigen‐specific killing activity against tumor cells | |
| Navarro et al. | PARP-1/PARP-2 double deficiency in mouse T cells results in faulty immune responses and T lymphomas | |
| Gomes-Santos et al. | New insights into the immunological changes in IL‐10‐deficient mice during the course of spontaneous inflammation in the gut mucosa | |
| Degl'Innocenti et al. | Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+ CD25+ regulatory T cells | |
| Davis et al. | Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients | |
| Mosaheb et al. | Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity | |
| Tu et al. | Myeloid suppressor cells induced by retinal pigment epithelial cells inhibit autoreactive T-cell responses that lead to experimental autoimmune uveitis | |
| Cheung et al. | Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer | |
| Meadors et al. | Murine rhabdomyosarcoma is immunogenic and responsive to T‐cell‐based immunotherapy | |
| Dieckmann et al. | Activated CD4+ CD25+ T cells suppress antigen‐specific CD4+ and CD8+ T cells but induce a suppressive phenotype only in CD4+ T cells | |
| Vinuesa et al. | Tracking the response of Xid B cells in vivo: TI‐2 antigen induces migration and proliferation but Btk is essential for terminal differentiation | |
| Zierden et al. | Effects and regulation of autoreactive CD8+ T cells in a transgenic mouse model of autoimmune hepatitis | |
| Nanni et al. | Antimetastatic activity of a preventive cancer vaccine | |
| Zheng et al. | Heat shock factor 1‐independent activation of dendritic cells by heat shock: implication for the uncoupling of heat‐mediated immunoregulation from the heat shock response | |
| Zheng et al. | Expression of tissue‐specific autoantigens in the hematopoietic cells leads to activation‐induced cell death of autoreactive T cells in the secondary lymphoid organs | |
| Lambolez et al. | Tolerance induction to self antigens by peripheral dendritic cells | |
| Chung et al. | Anatomic location defines antigen presentation by dendritic cells to T cells in response to intravenous soluble antigens | |
| Liu et al. | Leveraging the Treg-intrinsic CTLA4–PKCη signaling pathway for cancer immunotherapy | |
| DeLuca et al. | Tolerance to the neuron-specific paraneoplastic HuD antigen |